A phase 3 clinical trial finds an anti-inflammatory drug used in rheumatoid arthritis can preserve lung function in patients with systemic sclerosis.
Tag: Tocilizumab
Protein Linked to Progressive Lung Scarring in Scleroderma Patients
Osteopontin is discovered as the culprit behind these patients’ main cause of death. However, a repurposed immunosuppressive drug may combat the pro-inflammatory protein.
.@UChicagoMedicine experts can discuss #Tocilizumab research; Drug may reduce need for ventilators in #COVID19 pneumonia
Roche made news today as research showed its drug (tocilizumab) reduced patients’ need for ventilators for those with COVID-19-associated pneumonia. A University of Chicago Medicine team has done separate, independent research on tocilizumab and found similar results in their own phase II trial.…
Hackensack Meridian Health Observational Study Identifies Drug that Improves Survival in Sickest COVID-19 Patients
A drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically-ill patients admitted to the intensive care unit (ICU), according to findings published in The Lancet Rheumatology.
COVID-19: Patients Improve After Immune-Suppressant Treatment
Most patients hospitalized with COVID-19 (coronavirus) pneumonia experienced improvement after receiving a Food and Drug Administration-approved drug normally given for rheumatoid arthritis, according to an observational study at Cedars-Sinai. Outcomes for patients who received the drug, tocilizumab, included reduced inflammation, oxygen requirements, blood pressure support and risk of death, compared with published reports of illness and death associated with severely ill COVID-19 patients.